LCH-I-S (1994-1998)

This salvage therapy trial was opened in 1994, in which the questions asked were whether it was possible to improve survival for MS-LCH patients whose disease progressed on current ‘‘best’’ therapy, and whether it was possible to cure those patients.¹ This salvage trial proposed a switch to bone marrow transplantation for patients with available matched sibling donor, or to immunosuppressive therapy (IST) with antithymocyte globulin, prednisone and cyclosporine (CSA) for patients without matched sibling donor. Due to poor patient entry, this trial was closed prematurely in 1998. From the composite data available and under the conditions it was used, the only conclusion possible was that CSA is of limited value in the treatment of MS-LCH resistant to standard combination chemotherapy.¹

^REFERENCES:

1. Minkov M, Grois N, Broadbent V, Ceci A, Jakobson A, Ladisch S. Cyclosporine A therapy for multisystem langerhans cell histiocytosis. Med Pediatr Oncol, 1999, 33(5):482-5.

Return to Previous HS Trials